Navigation Links
Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Date:3/2/2009

ave difficulty returning to sleep. Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted a New Drug Application (NDA) for Intermezzo(R) to the U.S. Food and Drug Administration (FDA) which was accepted for filing on December 15, 2008. The FDA has assigned a PDUFA date of July 30, 2009, to the Intermezzo(R) NDA.

For further information, please visit the company's website at: www.transcept.com.

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Intermezzo(R) being the first commercially available sleep aid in its target indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, or unexpected expenses incurred in connection with, obtaining regulatory approval, market acceptance and commercialization of Intermezzo(R).

    Contacts:

    Transcept Pharmaceuticals, Inc.
    Michael Gill
    Director of Communications
    (510) 215-3575
    mgill@transcept.com

    Th
'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... A UPMC and ... earned international recognition as a premier center for treatment of and research into ... internal bleeding and stroke. , Cure HHT, previously known as The HHT ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... naturopathic and allopathic medicine, opens its second location this week at 31542 S. ... 1000 square feet of lounge space for patients to relax while receiving safe ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ericson is a noted speaker and educator in ... Associate Director of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where ... Boot Camps. She serves as a CDI subject matter expert for a variety of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Administrators is taking action after seeing a significant increase in unlawful tactics ... Review division has found many cases of OON ASCs encouraging members to have ...
(Date:9/2/2015)... ... 2015 , ... The 2015 China Overseas Investment and Entrepreneurship ... conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai State ... feature leading EB-5 industry professionals and Chinese private equity partners looking for international ...
Breaking Medicine News(10 mins):Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2
... KNOXVILLE, Tenn.--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) announced preliminary results ... the treatment of metastatic melanoma, the most aggressive form ... efficacy and bystander effect on melanoma tumors in stage ... Provecta in a total of 20 subjects at two ...
... infectious diseases and developing preventive vaccines is the ability ... response over time. An Emory-led team of scientists has ... are able to evade the immune response. The ... of the National Academy of Sciences. , Using a ...
... (TB) experts at Johns Hopkins and in Brazil have ... of drugs used to treat the highly contagious form ... to cure the illness from six months to four. ... antibiotics increased by 17 percent the number of patients ...
... survey [1] analysing how cancer research is funded ,shows ... contributor to the global ,cancer research effort. , Prof ... Forum (ECRM), launched the organisations second survey, which looks ... 2004, at the European Parliament today (Tuesday 18 September). ...
... a Year, TAMPA, Fla., Sept. 18 In response ... a two-week coma with a craving for The,Melting Pot, the ... The Melting Pot will fly Jill Finley and her family ... at its annual,meeting. On May 26, Finley,s husband Ryan ...
... College of Medicine of Yeshiva University has been awarded a ... of Health to further the medical schools study of centenarians ... Nir Barzilai, director of Einsteins Institute for Aging Research, the ... genes that appear to contribute to exceptional longevity in humans, ...
Cached Medicine News:Health News:Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study 2Health News:Chronic infection persists by targeting stromal cell network in lymphoid organs 2Health News:New antibiotic drug combo to speed up treatment of tuberculosis 2Health News:New antibiotic drug combo to speed up treatment of tuberculosis 3Health News:New antibiotic drug combo to speed up treatment of tuberculosis 4Health News:Launch of second European Cancer Research Funding survey 2Health News:Launch of second European Cancer Research Funding survey 3Health News:Launch of second European Cancer Research Funding survey 4Health News:Update on Jill Finley Story, Coma Survivor 2Health News:NIH awards Einstein multimillion dollar grant to extend studies of exceptional longevity 2
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) ... Device Studies: Clinical Evidence (London, UK - November ... This course has been designed specifically ... evidence required for medical devices and in-vitro diagnostic ... devices and the emphasis on high quality, appropriate ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. ... Coughlin , Chief Financial Officer of Neurocrine Biosciences, will ... New York City . ... at 11:25am ET (8:25am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. Advances in understanding of ... new avenues and possibilities for improved drug delivery ... enzymes, and receptors that control the penetration of ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... PSTX) today announced that The Mount Sinai Hospital in New York City has implemented its Safety-Sponge System. , ... , , ... ... ...
... N.J. , March 15 Regado Biosciences, Inc., ... with active control agents, announced that Chris Rusconi , ... Zelenkofske , DO, FACC, Senior Vice President , Chief Medical ... on Monday, March 15, 2010 in Atlanta, ...
Cached Medicine Technology:Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 2Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: